Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
Peripheral Levels of Fibrinogen, C-Reactive Protein, and Plasma Viscosity Predict Future Cognitive Decline in Individuals Without Dementia
Psychosomatic Medicine, 08/17/09
Riccardo EM et al. – Increased circulating levels of CRP, fibrinogen, and elevated plasma viscosity predicted poorer subsequent cognitive ability and were associated with age–related cognitive decline in several domains, including general ability.
Methods- Subjects consisted of 2312 men and women aged 50 to 80 years participating in the Aspirin for Asymptomatic Atherosclerosis Trial, all of whom were free of symptomatic cardiovascular disease at baseline.
- Biomarker levels and cognitive ability were measured at baseline with cognition assessed in all subjects using the Mill Hill Vocabulary Scale and in a subgroup of 504 persons using tests of memory, nonverbal reasoning, information processing speed, executive function, and mental flexibility.
- After 5 years, the five–test battery was administered to all participants and scores were used to derive a general cognitive ability factor.
- Baseline CRP and fibrinogen levels were associated negatively with age and sex–adjusted follow–up scores on the majority of the cognitive tests, and the general cognitive ability factor (correlations = –0.054 to 0.105, p < .05).
- In analyses adjusting for baseline cognitive scores, asymptomatic atherosclerotic disease, and cardiovascular risk factors, both markers predicted decline in several cognitivedomains (excluding memory).
- Baseline plasma viscosity, but not hematocrit, was associated negatively with follow–up test scoresfor general cognitive ability, information processing speed, and mental flexibility (correlations = –0.050 to –0.098, p < .05) and with decline across the same domains (p < .05).
Today in Geriatric Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
What is the association between depression and Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
The Occurence of Mood and Anxiety Disorders in Heart Transplant Recipients
Transplantation Proceedings, 11/02/09
Today in Neuropsych Sciences...keeping you current
Receive free subspecialty "5-minute updates" via email
Impulsivity, personality and bipolar disorder
European Psychiatry , 11/06/09
The role of dopamine in bipolar disorder
Bipolar Disorders, 11/18/09
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis
Journal of Psychiatric Research, 11/20/09
Today in Other Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Today in Personality Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Impulsivity, personality and bipolar disorder
European Psychiatry , 11/06/09
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder
International Clinical Psychopharmacology, 10/23/09
Sponsor
Article Search
Sponsor


See Latest Articles


